Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxorubicin
Drug ID BADD_D00723
Description Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.
Indications and Usage Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Marketing Status approved; investigational
ATC Code L01DB01
DrugBank ID DB00997
KEGG ID D03899
MeSH ID D004317
PubChem ID 31703
TTD Drug ID D07VLY
NDC Product Code 12543-3209; 70121-1218
UNII 80168379AG
Synonyms Doxorubicin | Farmiblastina | Ribodoxo | Rubex | Adriamycin | Adriblastin | Adriblastine | Adriblastina | Adriablastine | Adriablastin | Adrimedac | DOXO-cell | DOXO cell | Urokit Doxo-cell | Urokit Doxo cell | Doxolem | Doxorubicin Hexal | Doxorubicin Hydrochloride | Hydrochloride, Doxorubicin | Doxorubicin NC | Doxorubicina Ferrer Farm | Doxorubicina Funk | Doxorubicina Tedec | Doxorubicine Baxter | Doxotec | Myocet | Onkodox
Chemical Information
Molecular Formula C27H29NO11
CAS Registry Number 23214-92-8
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neutropenic sepsis11.01.11.006; 01.02.03.007--Not Available
Onychomadesis23.02.05.0060.000168%
General physical health deterioration08.01.03.0180.000672%Not Available
Tachyarrhythmia02.03.02.008--Not Available
Left ventricular dysfunction02.04.02.0110.001847%
Tumour haemorrhage24.07.01.028; 16.32.03.0080.000112%
Left ventricular hypertrophy02.04.02.0140.000112%Not Available
Cardiac death08.04.01.007; 02.03.04.0150.000112%Not Available
Anal inflammation07.03.03.0040.000168%
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000112%Not Available
Ventricular hypokinesia02.04.02.0130.000168%Not Available
Ejection fraction decreased13.14.02.003--
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Lower gastrointestinal haemorrhage07.12.03.011; 24.07.02.0300.000112%
Nodular regenerative hyperplasia09.01.04.0040.000112%Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000112%Not Available
Chylothorax22.05.02.0060.000280%
Madarosis23.02.02.004; 06.06.04.0100.000873%Not Available
Facial paresis17.04.03.0020.000112%
Malignant neoplasm progression16.16.01.0050.001847%Not Available
Necrotising colitis07.08.01.013--Not Available
Metastases to peritoneum16.22.02.008; 07.21.03.0030.000168%Not Available
Haemodynamic instability24.03.02.0060.000224%Not Available
Lymphatic disorder01.09.01.003--Not Available
Diastolic dysfunction02.04.02.0220.001063%Not Available
Phlebosclerosis24.04.02.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Febrile bone marrow aplasia08.05.02.005; 01.03.03.0070.000280%Not Available
Infusion site pain12.07.05.002; 08.02.05.0140.000604%Not Available
Infusion site oedema12.07.05.013; 08.02.05.0120.000112%Not Available
The 19th Page    First    Pre   19 20 21 22 23    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene